Savara (NASDAQ:SVRA) Trading Down 6.6%

Savara Inc (NASDAQ:SVRA - Get Free Report)'s stock price traded down 6.6% during trading on Wednesday . The stock traded as low as $4.38 and last traded at $4.38. 242,565 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 837,078 shares. The stock had previously closed at $4.69.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SVRA shares. Piper Sandler increased their price objective on shares of Savara from $7.00 to $16.00 and gave the company an "overweight" rating in a research report on Monday, March 4th. JMP Securities reissued a "market outperform" rating and issued a $8.00 price target on shares of Savara in a report on Thursday, April 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Savara presently has a consensus rating of "Buy" and an average price target of $8.20.

Savara Trading Down 9.6 %

The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $585.76 million, a P/E ratio of -13.27 and a beta of 0.77. The business has a 50-day moving average price of $4.96 and a two-hundred day moving average price of $4.42.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, analysts expect that Savara Inc will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in Savara during the third quarter worth $140,000. Bank of New York Mellon Corp increased its holdings in Savara by 20.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 261,435 shares of the company's stock worth $988,000 after purchasing an additional 44,641 shares in the last quarter. Jennison Associates LLC grew its holdings in Savara by 44.6% during the third quarter. Jennison Associates LLC now owns 3,866,762 shares of the company's stock worth $14,616,000 after buying an additional 1,192,730 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Savara in the third quarter valued at about $48,000. Finally, Jump Financial LLC purchased a new stake in Savara in the 3rd quarter valued at about $123,000. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.